New combo therapy aims to outsmart aggressive lymphoma

NCT ID NCT04546620

Ongoing Disease control Sponsor: University Hospital Southampton NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) improves outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 450 participants will receive one cycle of R-CHOP, then two-thirds will get five more cycles with acalabrutinib, while the rest continue R-CHOP alone. The study tracks how long patients live without their cancer progressing or returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acalabrutinib (a targeted cancer drug) added to standard chemotherapy (R-CHOP)

What this could lead to

If successful, this could lead to a more effective first-line treatment for certain types of diffuse large B-cell lymphoma, potentially delaying or preventing relapse.

What could go wrong

This is a mid-stage trial, so results are not yet proven. Adding acalabrutinib may increase side effects without improving outcomes, and benefits may only apply to specific lymphoma subtypes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Addenbrooke's Hospital

Cambridge, United Kingdom
Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom
Chase Farm and Barnet Hospitals

London, United Kingdom
Churchill Hospital

Oxford, United Kingdom
Colchester General Hospital

Colchester, Essex, United Kingdom
Derriford Hospital

Plymouth, United Kingdom
East Kent Hospitals NHS Foundation Trust

Canterbury, Kent, United Kingdom
Freeman Hospital

Newcastle, United Kingdom
Ipswich Hospital

Ipswich, United Kingdom
Leicester Royal Infirmary

Leicester, United Kingdom
Lewisham and Greenwich NHS Trust

London, United Kingdom
Maidstone Hospital

Maidstone, United Kingdom
Milton Keynes University Hospital

Milton Keynes, United Kingdom
Monklands Hospital

Airdrie, United Kingdom
Norfolk and Norwich University Hospital

Norwich, United Kingdom
Nottingham City Hospital

Nottingham, United Kingdom
Queen Alexandra Hospital

Portsmouth, United Kingdom
Queen's Hospital

Romford, United Kingdom
Queens Hospital

Burton-on-Trent, United Kingdom
Royal Cornwall Hospital

Truro, United Kingdom
Royal Derby Hospital

Derby, United Kingdom
Royal Devon and Exeter Hospital

Exeter, United Kingdom
Royal Oldham Hospital

Oldham, United Kingdom
Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom
Singleton Hospital

Swansea, United Kingdom
Southampton General Hospital

Southampton, United Kingdom
St James Hospital

Leeds, United Kingdom
The Christie Hospital

Manchester, United Kingdom
Torbay Hospital

Torquay, United Kingdom
University College London Hospital

London, United Kingdom
University Hospital Dorset NHS Foundation Trust (Bournemouth and Poole Hospitals)

Bournemouth, United Kingdom
Victoria Hospital

Blackpool, United Kingdom
Worthing and St Richards Hospitals

Worthing, United Kingdom